BioRestorative Therapies, Inc. (NASDAQ:BRTX) Sees Significant Decrease in Short Interest

BioRestorative Therapies, Inc. (NASDAQ:BRTX) saw a significant decrease in short interest in July. As of July 31st, there was short interest totalling 73,600 shares, a decrease of 48.9% from the July 15th total of 144,000 shares. Approximately 1.3% of the company’s shares are short sold. Based on an average trading volume of 1,640,000 shares, the days-to-cover ratio is presently 0.0 days.

BioRestorative Therapies Price Performance

BRTX traded down $0.01 during trading on Wednesday, reaching $1.40. The company had a trading volume of 26,475 shares, compared to its average volume of 1,077,727. The business’s fifty day moving average price is $1.68 and its 200 day moving average price is $1.50. BioRestorative Therapies has a 12 month low of $1.03 and a 12 month high of $3.67. The company has a market cap of $9.48 million, a P/E ratio of -0.61 and a beta of 63.47.

BioRestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.06. The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.03 million. BioRestorative Therapies had a negative net margin of 7,303.33% and a negative return on equity of 96.09%. During the same period in the previous year, the firm posted ($0.77) EPS. As a group, sell-side analysts predict that BioRestorative Therapies will post -2.36 EPS for the current fiscal year.

Institutional Investors Weigh In On BioRestorative Therapies

An institutional investor recently bought a new position in BioRestorative Therapies stock. StoneX Group Inc. purchased a new stake in shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 34,850 shares of the company’s stock, valued at approximately $48,000. StoneX Group Inc. owned about 0.51% of BioRestorative Therapies as of its most recent filing with the Securities and Exchange Commission (SEC). 69.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Roth Mkm lifted their price objective on BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.